Allergan tries to lure Inamed from Medicis deal with sweeter $3.2bn offer
This article was originally published in Clinica
Executive Summary
Allergan, the diversified healthcare company best known in consumer circles for its Botox antiwrinkle treatment, may have triggered a bidding war for Inamed after it proposed to acquire the breast implant maker for $3.2bn, outdoing an earlier offer made by Medicis Pharmaceuticals.